R-CHOP
Aliases
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, 1, 2-Dehydrocortisone, 2-Dehydrocortisone, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), Adasone (152 other aliases)
302 clinical trials
47 products
15 abstracts
478 indications
10 targets
Indication
Diffuse Large B Cell LymphomaIndication
mantle cell lymphomaIndication
UntreatedIndication
Multiple MyelomaIndication
Prostate CancerIndication
Acute Lymphoblastic LeukemiaIndication
AcuteIndication
ChildhoodIndication
LeukemiaIndication
LymphoblasticIndication
T cellIndication
Ovarian CancerIndication
Endometrial NeoplasmsIndication
Cervical CancerIndication
Vulvar CancerIndication
Vaginal NeoplasmIndication
Clear Cell CarcinomaIndication
Crohn's diseaseIndication
Diffuse Large B-Cell LymphomaIndication
Burkitt lymphomaIndication
Multicentric Castleman DiseaseIndication
hepatoblastomaIndication
cancerIndication
HepatocellularIndication
T Lymphoblastic LymphomaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Breast Inflammatory CarcinomaIndication
Breast CarcinomaIndication
Breast CancerIndication
Stage III Breast CancerIndication
Stage IIIA Breast CancerIndication
Breast cancerIndication
Cardiac SarcoidosisIndication
B Lymphoblastic LymphomaIndication
Mixed Phenotype Acute LeukemiaIndication
Testicular LeukemiaIndication
Bladder CancerIndication
RhabdomyosarcomaIndication
Alveolar RhabdomyosarcomaIndication
Spindle Cell/Sclerosing RhabdomyosarcomaIndication
Stage II Breast CancerIndication
Triple-Negative Breast CarcinomaIndication
Lymphoblastic LymphomaIndication
Acute Heart FailureIndication
PediatricIndication
GlomerulonephritisIndication
Immunoglobulin A deficiencyIndication
Castration-Resistant Prostate CarcinomaIndication
Prostate Cancer, Stage IV AJCC v7Indication
Low Back PainIndication
OsteoarthritisIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Malignant Solid NeoplasmIndication
MedulloblastomaIndication
Hodgkin lymphomaIndication
Systemic Lupus ErythematosusIndication
HealthyIndication
Soft Tissue SarcomaIndication
Acute lymphoblastic leukemiaIndication
Follicular LymphomaIndication
Inflammatory CardiomyopathyIndication
MyocarditisIndication
Tuberculous LymphadenitisIndication
cervicalIndication
Stage I Hodgkin LymphomaIndication
Hodgkin LymphomaIndication
Hodgkin lymphoma, Ann Arbor stage IBIndication
Hodgkin Lymphoma Stage IIIndication
Hodgkin Lymphoma, Ann Arbor Stage IIBIndication
Recurrent Acute Myeloid LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Recurrent T Acute Lymphoblastic LeukemiaIndication
Acute Myeloid LeukemiaIndication
Stage 1 cT1b-T1cN0M0Indication
Triple-Negative Breast CancerIndication
Acute Liver FailureIndication
Fulminant Hepatic FailureIndication
Hepatic EncephalopathyIndication
Acute Liver InjuryIndication
Immune DysregulationIndication
Mature B-cell Non-Hodgkin LymphomaIndication
UveitisIndication
posteriorIndication
IntermediateIndication
PanuveitisIndication
Wilms tumorIndication
Facial PalsyIndication
Facial Nerve DisordersIndication
Lyme NeuroborreliosisIndication
Bell's PalsyIndication
Marginal Zone LymphomaIndication
Stage III Follicular LymphomaIndication
Stage IV Follicular LymphomaIndication
High Grade B-Cell Lymphoma With MYCIndication
B-cell lymphoma 2Indication
BCL6 RearrangementsIndication
Indolent Non-Hodgkin LymphomaIndication
BCR-ABL1-likeIndication
Acute lymphoblastic leukemia, adult typeIndication
Adult L1 Acute Lymphoblastic LeukemiaIndication
Adult T Acute Lymphoblastic LeukemiaIndication
Adult Acute Lymphoblastic LeukemiaIndication
Chronic GVHDIndication
Advanced LeiomyosarcomaIndication
LeiomyosarcomaIndication
Acute Leukemia of Ambiguous LineageIndication
Ewing SarcomaIndication
NK-Cell LymphomaIndication
NK Cell LeukemiaIndication
Peripheral T Cell LymphomaIndication
Complex Regional Pain SyndromesIndication
Wrist FracturesIndication
Wilms TumorIndication
Duchenne Muscular DystrophyIndication
Richter syndromeIndication
Chronic Lymphocytic LeukemiaIndication
Pediatric StrokeIndication
Lupus NephritisIndication
Prostate Cancer, Stage III AJCC v8Indication
Prostate Cancer Stage IIIB AJCC v8Indication
CancerIndication
Adrenal InsufficiencyIndication
AsthmaIndication
Chronic Obstructive Pulmonary DiseaseIndication
Muscular DystrophyIndication
DuchenneIndication
RetinoblastomaIndication
OsteoporosisIndication
Abnormal DNA RepairIndication
MRDIndication
Genetic AbnormalityIndication
Chemotherapy ToxicityIndication
Congestive Heart FailureIndication
Endomyocardial BiopsyIndication
CardiomyopathyIndication
SecondaryIndication
Immune suppressionIndication
lymphomaIndication
Plasmablastic LymphomaIndication
Stage I Diffuse Large B-Cell LymphomaIndication
Hepatocellular CarcinomaIndication
Adult Lymphoblastic LymphomaIndication
Deleterious HRR Gene MutationIndication
BRCA1 Gene MutationIndication
BRCA2Indication
BRIP1 Gene MutationIndication
CHEK2 mutationIndication
Fanconi anemiaIndication
PALB2 Gene MutationIndication
RAD51BIndication
RAD54L Gene MutationIndication
Stage II Childhood Hodgkin LymphomaIndication
Liver CancerIndication
Childhood Hodgkin LymphomaIndication
BCR-ABL1-positiveIndication
Breast Cancer, Stage IVIndication
AnaemiaIndication
Non-Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Stage IV Non-Hodgkin LymphomaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
Pancreatic CancerIndication
Metastatic Malignant Solid NeoplasmIndication
UnclassifiableIndication
Primary MyelofibrosisIndication
Recurrent Hematologic MalignancyIndication
Myelodysplastic SyndromeIndication
Myeloproliferative NeoplasmIndication
Small Lymphocytic LymphomaIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Refractory Hematologic MalignancyIndication
Hodgkin's LymphomaIndication
Refractory Non-Hodgkin LymphomaIndication
MyelofibrosisIndication
Stage III Pancreatic CancerIndication
Inflammatory ArthritisIndication
Immune-related Adverse EventIndication
GlaucomaIndication
Pancreatic AdenocarcinomaIndication
Chronic RhinosinusitisIndication
High-grade B-cell lymphomaIndication
Allergic Bronchopulmonary AspergillosisIndication
Breast Cancer, Stage IIIndication
Epstein-Barr Virus InfectionsIndication
Chemotherapeutic Agent ToxicityIndication
Cognitive/Functional EffectsIndication
NeurotoxicityIndication
Radiation ToxicityIndication
Pulmonary DiseaseIndication
Solid TumorIndication
urethral cancerIndication
Aggressive B-cell LymphomaIndication
Castration Levels of TestosteroneIndication
prostate-specific antigen progressionIndication
Prostate AdenocarcinomaIndication
AdultIndication
Philadelphia-Negative ALLIndication
Non-Hodgkin lymphomaIndication
Blood CancerIndication
Male Breast CancerIndication
Breast Cancer, Stage IIAIndication
Chronic ObstructiveIndication
Adverse Effects of GlucocorticoidsIndication
ExacerbationIndication
Hodgkin lymphoma, AIDS-relatedIndication
Hodgkin Lymphoma, Ann Arbor Stage IVAIndication
Stage IVB Hodgkin LymphomaIndication
Lung Transplant ComplicationsIndication
Chronic obstructive pulmonary diseaseIndication
PneumonitisIndication
Acute Lymphoblastic LymphomaIndication
Chronic RejectionIndication
Kidney InsufficiencyIndication
B-Cell Non-Hodgkin LymphomaIndication
Diffuse Large B-cell LymphomaIndication
Beckwith-Wiedemann SyndromeIndication
Rhabdoid Tumor of the KidneyIndication
HIV InfectionIndication
Castration-resistant Prostate CancerIndication
Barrett's EsophagusIndication
Esophageal StenosisIndication
Recurrent B Lymphoblastic LymphomaIndication
Stage IIIB Breast CancerIndication
Stage IV Breast Cancer AJCC v8Indication
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageIndication
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic LeukemiaIndication
KMT2A RearrangedIndication
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaIndication
Arteritis, Giant CellIndication
Takayasu arteritisIndication
Cogan SyndromeIndication
Relapsing polychondritisIndication
Cryoglobulinemic VasculitisIndication
Henoch-Schönlein purpuraIndication
polyarteritis nodosaIndication
Cutaneous Polyarteritis NodosaIndication
COVID-19Indication
RemodelingIndication
Left VentricleIndication
VascularIndication
Left Ventricular DysfunctionIndication
Exercise IntoleranceIndication
VasculitisIndication
Microvascular anginaIndication
Ph-Like Acute Lymphoblastic LeukemiaIndication
Stage IIA Breast CancerIndication
Advanced Solid TumorIndication
Primary Effusion LymphomaIndication
B-cell NeoplasmIndication
NOSIndication
Double-Expressor LymphomaIndication
High-Grade B-Cell LymphomaIndication
B-cell Acute Lymphoblastic LeukemiaIndication
Chronic Sinus DiseaseIndication
EthmoidalIndication
SphenoidalIndication
Chronic Sinusitis - Maxillary BilateralIndication
Chronic Sinusitis - FrontoethmoidalIndication
Castrate-Sensitive Prostate CancerIndication
Oligometastatic DiseaseIndication
Mantle Cell LymphomaIndication
Classical Hodgkin LymphomaIndication
Hodgkin lymphoma, mixed cellularityIndication
Childhood Solid NeoplasmIndication
NeuroblastomaIndication
CD79A gene mutationIndication
CD79B Gene MutationIndication
Early Breast CancerIndication
Neoadjuvant TherapyIndication
HR+HER2- Breast CancerIndication
Bone SarcomaIndication
Pulmonary MetastasesIndication
Limb-girdle Muscular DystrophyIndication
Becker Muscular DystrophyIndication
Stage II Non-Hodgkin LymphomaIndication
Alcoholic HepatitisIndication
AnosmiaIndication
Merkel Cell CarcinomaIndication
Stage IV Cutaneous MelanomaIndication
Stage IV Cutaneous Merkel Cell CarcinomaIndication
Basal Cell CarcinomaIndication
Metastatic MelanomaIndication
Squamous Cell CarcinomaIndication
Cutaneous MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Cutaneous Merkel Cell CarcinomaIndication
melanomaIndication
ulcerative colitisIndication
Philadelphia Chromosome NegativeIndication
Prostate cancerIndication
Breast NeoplasmsIndication
Rheumatoid ArthritisIndication
B-cellIndication
Adult Soft Tissue SarcomaIndication
lung cancerIndication
Lung MetastasesIndication
Osteoarthritis, KneeIndication
Prostate CarcinomaIndication
SarcomaIndication
Acute Lymphocytic LeukemiaIndication
Sudden Sensorineural Hearing LossIndication
Angioimmunoblastic T-cell LymphomaIndication
Enteropathy-Associated T-Cell LymphomaIndication
Follicular T-Cell LymphomaIndication
Peripheral T-Cell LymphomaIndication
Melanoma stage IIIIndication
Skin Cancer Stage IIIIndication
Skin CancerIndication
Drug-Induced ColitisIndication
Drug ToxicityIndication
pericarditisIndication
Acute Exacerbation of COPDIndication
CorticosteroidIndication
MortalityIndication
Lung DiseasesIndication
ObstructiveIndication
Eosinophil CountIndication
IgG4-Related DiseaseIndication
Renal Cell CarcinomaIndication
Erythema Nodosum LeprosumIndication
Asthma in ChildrenIndication
Localized Soft Tissue SarcomaIndication
Unresectable Sinonasal TumorsIndication
LiverIndication
Cancer ofIndication
Primary ResectableIndication
Idiopathic orbital inflammatory syndromeIndication
B-cell LymphomaIndication
Soft-tissue sarcomaIndication
Osteoarthritis of the KneeIndication
Platelet-rich plasmaIndication
ResectableIndication
Langerhans Cell HistiocytosisIndication
T-cell non-Hodgkin lymphomaIndication
Community-acquired PneumoniaIndication
Cognitive DisorderIndication
Immune ThrombocytopeniaIndication
GlucocorticoidsIndication
OnlyIndication
Minimal Change DiseaseIndication
nephrotic syndromeIndication
Facial SwellingIndication
MalocclusionIndication
Dental CariesIndication
ImpactedIndication
Dental AvulsionIndication
AIDS-related plasmablastic lymphomaIndication
AIDS-related primary effusion lymphomaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Grade 3 Follicular LymphomaIndication
Soft TissueIndication
Undifferentiated Pleomorphic SarcomaIndication
LiposarcomaIndication
Synovial SarcomaIndication
MyxofibrosarcomaIndication
AngiosarcomaIndication
fibrosarcomaIndication
Malignant Peripheral Nerve Sheath TumorIndication
Epithelioid SarcomaIndication
tendinopathyIndication
ArthritisIndication
RheumatoidIndication
GliomaIndication
Pilocytic AstrocytomaIndication
Anaplastic AstrocytomaIndication
GlioblastomaIndication
Mixed OligoastrocytomaIndication
Mixed GliomaIndication
OligodendrogliomaIndication
AstrocytomaIndication
SarcoidosisIndication
PulmonaryIndication
Resectable SarcomaIndication
Mild Cognitive ImpairmentIndication
Membranous NephropathyIndication
Frozen ShoulderIndication
Adult T-Cell Leukemia/LymphomaIndication
Anaplastic Large Cell LymphomaIndication
ALK-NegativeIndication
ALK-positiveIndication
Angioimmunoblastic T-Cell LymphomaIndication
Hepatosplenic T-Cell LymphomaIndication
AIDS-related lymphomaIndication
Thrombotic Thrombocytopenic PurpuraIndication
Adult Diffuse Large Cell LymphomaIndication
Kidney TransplantIndication
Renal Transplant RecipientsIndication
BCR-ABL1 Fusion Protein ExpressionIndication
Philadelphia Chromosome PositiveIndication
t(9;22)Indication
Trigger FingerIndication
Percutaneous A1 Pulley ReleaseIndication
intra-articular corticosteroid injectionIndication
Postoperative PainIndication
lymphoproliferative disorderIndication
HHV-8Indication
HIVIndication
Resectable NeuroblastomaIndication
Pulmonary Arterial HypertensionIndication
Connective Tissue DiseasesIndication
Pregnancy RelatedIndication
Fanconi AnemiaIndication
Bronchiolitis Obliterans SyndromeIndication
Bronchiolitis ObliteransIndication
Chronic Graft Versus Host DiseaseIndication
Newly Diagnosed PatientsIndication
HER2/Neu PositiveIndication
Progesterone Receptor PositiveIndication
Breast Cancer Stage IB AJCC v7Indication
Aggressive Non-Hodgkin LymphomaIndication
ALK-Positive Large B-Cell LymphomaIndication
B-cell lymphomaIndication
Geographic AtrophyTarget
GnRH receptorTarget
PSATarget
ECOGTarget
CD20Target
DNA topoisomerase IITarget
TubulinTarget
DNATarget
Cyclophosphamide targetsTarget
glucocorticoid receptorIndication
Chemotherapy effectsIndication
Safety IssuesIndication
Radionecrosis of BrainIndication
Brain MetastasesIndication
Transplant rejectionIndication
kidneyIndication
PancreasIndication
Heart TransplantIndication
Friedreich AtaxiaIndication
GoutIndication
chronic kidney diseaseIndication
kidney transplantAbstract
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.Org: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital),
Abstract
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.Org: Department of Hematology,The First Affiliated Hospital of Chongqing Medical University, Department of Hematology and Oncology, Chongqing University Cancer Hospital, Department of Hematology Oncology, YunNan Provincial Cancer Hospital, Department of Lymphoma Medicine, Hubei Cancer Hospital, Department of Lymphoma and Hematology, Hunan Cancer Hospital,
Abstract
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.Org: Mayo Clinic, Mayo Clinic Florida,
Clinical trial
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III StudyStatus: Recruiting, Estimated PCD: 2033-03-31
Clinical trial
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-15
Clinical trial
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II StudyStatus: Completed, Estimated PCD: 2023-11-07
Clinical trial
A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaStatus: Terminated, Estimated PCD: 2023-03-13
Clinical trial
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2018-03-19
Clinical trial
A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)Status: Terminated, Estimated PCD: 2012-01-10
Clinical trial
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV07/ ENGOT-ov80 Study)Status: Not yet recruiting, Estimated PCD: 2027-08-31
Clinical trial
Top-down Infliximab Study in Kids With Crohn's DiseaseStatus: Completed, Estimated PCD: 2019-12-01
Abstract
Rituximab, chidamide, and zanubrutinib (ZCR) ± CHOP as a regimen for treatment naive (TN) double-expressor DLBCL (DE-DLBCL).Org: Affiliated Dongguan People’s Hospital, Dongguan People’s Hospital,
Abstract
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).Org: Hematology Oncology of Indiana/American Oncology Network, Azienda Unità Sanitaria Locale-IRCCS, Gazi Universitesi Tip Fakültesi, ProHealth Care,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Real-world cost of disease progression (PD) after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL): An analysis of a large US claims database.Org: Rocky Mountain Cancer Centers, The US Oncology Network, Aurora, CO, Genentech, South San Francisco, CA,
Abstract
Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.Org: Shandong Provincial Qianfoshan Hospital,
Clinical trial
A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With AcalabrutinibStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in UgandaStatus: Terminated, Estimated PCD: 2023-07-26
Clinical trial
Paediatric Hepatic International Tumour TrialStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IStatus: Active (not recruiting), Estimated PCD: 2022-05-10
Clinical trial
A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic LymphomaStatus: Withdrawn, Estimated PCD: 2026-09-22
Clinical trial
Molecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac SarcoidosisStatus: Completed, Estimated PCD: 2018-12-01
Clinical trial
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBCStatus: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLyStatus: Recruiting, Estimated PCD: 2030-03-31
Clinical trial
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)Status: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative RhabdomyosarcomaStatus: Recruiting, Estimated PCD: 2030-12-31
Clinical trial
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Status: Recruiting, Estimated PCD: 2028-07-14
Clinical trial
A Phase I/II Study to Investigate the Combination of LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory T-ALL/LBLStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Multicenter, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF)Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2019-10-16
Clinical trial
Platelet-rich Plasma Infiltration Versus Corticosteroid Infiltration (Prednisolone) in Treatment of Lumbar Facet Joint SyndromeStatus: Recruiting, Estimated PCD: 2023-12-21
Clinical trial
A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA MethodsStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed MedulloblastomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children With Previously Untreated Intermediate- and High-risk Classical Hodgkin's Lymphoma: an Open Label, Non-randomized, Single-arm, Phase 2 Study From Single CenterStatus: , Estimated PCD: 2024-12-31
Clinical trial
Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
CIRcadian Rhythms and CortisoL. Effects on Substrate Metabolism and Clock Gene Expression and FunctioningStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2020-11-30
Clinical trial
Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma of Extremities and Trunk WallStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Study on the Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) of the Liver Following Allogeneic Hematopoietic Stem Cell TransplantatioStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
A TACL Phase 1/2 Study of PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma IND# 140730Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular LymphomaStatus: Recruiting, Estimated PCD: 2028-11-01
Clinical trial
Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue SarcomasStatus: Recruiting, Estimated PCD: 2025-06-20
Clinical trial
The Efficacy and Mechanism of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy After MyocarditisStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Role of Low Dose Steroids vs Placebo in Addition to Anti-tuberculosis Treatment (ATT) in Regression of Lymph Node Sizes in Patients With Tuberculous LymphadenopathyStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2022-07-01
Clinical trial
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory LeukemiaStatus: Withdrawn, Estimated PCD: 2023-09-01
Clinical trial
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2018-06-01
Clinical trial
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric PatientsStatus: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and AdolescentsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
ALL Adult Consortium Trial: Adult ALL TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Ozurdex as Monotherapy for Treatment of Non-infectious Intermediate, Posterior, or PanuveitisStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple MyelomaStatus: Completed, Estimated PCD: 2008-02-01
Clinical trial
A Phase1 Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms TumorStatus: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-05-15
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)Status: Active (not recruiting), Estimated PCD: 2016-06-01
Clinical trial
SHR0302 and Prednisone as First Line Therapy for Chronic Graft Versus Host Disease Following Allogeneic Stem Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT): A Randomised Phase II Trial of Investigator Choice Standard Therapy Versus Sequential Novel Therapy Experimental ArmsStatus: Recruiting, Estimated PCD: 2029-05-31
Clinical trial
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in LeiomyosarcomaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of VenetoclaxStatus: Not yet recruiting, Estimated PCD: 2027-12-21
Clinical trial
A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing SarcomaStatus: Active (not recruiting), Estimated PCD: 2027-05-01
Clinical trial
Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Advanced ChemoHormonal Therapy for Treatment Naïve Metastatic Prostate Cancer: Apalutamide and Abiraterone Acetate With Prednisone and Androgen Deprivation Therapy After Treatment With Docetaxel and Androgen Deprivation TherapyStatus: Active (not recruiting), Estimated PCD: 2028-01-01
Clinical trial
Prednisone for the Early Treatment of Complex Regional Pain Syndrome After Distal Radius Fracture - a Pilot Randomized TrialStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)Status: Not yet recruiting, Estimated PCD: 2031-02-13
Clinical trial
Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle FunctionStatus: Recruiting, Estimated PCD: 2024-10-07
Clinical trial
Phase II Study of Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) TrialStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)Status: Active (not recruiting), Estimated PCD: 2024-08-16
Clinical trial
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate CancerStatus: Recruiting, Estimated PCD: 2026-06-07
Clinical trial
A Single-arm, Multi-center, Phase II Clinical Trial of R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Medium to High Risk/High Risk Diffuse Large B Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-11-29
Clinical trial
A Phase II Study of Durvalumab Treatment Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesStatus: Recruiting, Estimated PCD: 2030-04-30
Clinical trial
Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
The Use of Benralizumab, an Interleukin-5 Receptor-α Monoclonal Antibody as Treatment of Acute Exacerbations of Airways DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-02-19
Clinical trial
A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMDStatus: Terminated, Estimated PCD: 2021-09-27
Clinical trial
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary EnucleatedStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients With Classical Hodgkin Lymphoma, Including Elderly Patients.Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
Effect of Short-Term Prednisone Therapy on C-reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory MarkersStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsStatus: Active (not recruiting), Estimated PCD: 2026-12-16
Clinical trial
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative StudyStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Immunosuppression in Biopsy-proven Virus Negative Myocarditis or Inflammatory CardiomyopathyStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 1 Study to Evaluate Safety, Toxicity, and Potential Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent AsthmaStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell LymphomaStatus: Completed, Estimated PCD: 2012-10-01
Clinical trial
Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate CancerStatus: Completed, Estimated PCD: 2021-11-15
Clinical trial
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIVStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Comparative Study Between Prednisolone, Cerebrolysin in the Treatment of Bell's PalsyStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL PatientsStatus: Active (not recruiting), Estimated PCD: 2022-08-01
Clinical trial
Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studYStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma: A Prospective Cohort StudyStatus: Completed, Estimated PCD: 2023-12-15
Clinical trial
Pharmacogenetic Study in Hepatocellular Carcinoma Patients Underwent TACEStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)Status: Active (not recruiting), Estimated PCD: 2015-10-06
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Clinical trial
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose TherapyStatus: Active (not recruiting), Estimated PCD: 2014-01-18
Clinical trial
Early Adalimumab Induction for Treatment of Steroid Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis: A Pragmatic Randomized Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled TRial Evaluating Immunosuppressive Treatment in Patients With Chronic Virus-Negative Inflammatory cardiomyopaThY (TRINITY Trial)Status: Recruiting, Estimated PCD: 2027-03-28
Clinical trial
A Prospective Randomized Control Trial of Pilocarpine Use After Combined Cataract/Kahook Dual Blade SurgeryStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis . A Randomized Clinical TrialStatus: Completed, Estimated PCD: 2023-02-01
Clinical trial
Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Stereotactic Body Radiation Therapy and Intermittent Androgen Deprivation TherapyStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Multicentre Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Randomized Trial Comparing the Role of Prednisolone, Itraconazole, or Their Combination in Patients With Acute Stage of Allergic Bronchopulmonary AspergillosisStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Study to Evaluate the Efficacy and Safety of Genotype-guided Targeted Agents in Combination With POLA-RCHP VERSUS POLA-RCHP in Patients With Previously Untreated Diffuse Large B-cell LymphomaStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast CancerStatus: Completed, Estimated PCD: 2007-05-01
Clinical trial
Multicenter Randomized Two Arms Study Evaluating the Efficacy of Prophylactic Rituximab in Adult EBV Negative Kidney Transplant Recipients on Incidence of EBV Primary Infection and Post-transplant Lymphoproliferative DisordersStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaStatus: Completed, Estimated PCD: 2020-03-19
Clinical trial
Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The "RECUT"-Trial)Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination With Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's MacroglobulinemiaStatus: Terminated, Estimated PCD: 2011-12-01
Clinical trial
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Comparing the Efficacy and Safety of Reduced-dose Chemotherapy Followed by Blinatumomab Versus hyperCVAD as Induction Therapy for Newly Diagnosed Ph-negative B-ALL: a Multicenter, Radomized, Phase 2 StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-08-01
Clinical trial
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin LymphomaStatus: Completed, Estimated PCD: 2022-08-02
Clinical trial
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersStatus: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
The Efficacy and Safety of Cadonilimab(AK104) With Adriamycin for First-line Treatment of Advanced Soft Tissue Sarcoma: a Multicenter, Single-arm, Phase II Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2027-03-31
Clinical trial
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-10-15
Clinical trial
A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant RecipientsStatus: , Estimated PCD: 2026-06-30
Clinical trial
Efficacy and Safety of Oral Corticosteroids for the Treatment of Acute Exacerbations of COPD in General PracticeStatus: Completed, Estimated PCD: 2017-05-23
Clinical trial
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 PneumonitisStatus: Terminated, Estimated PCD: 2023-12-21
Clinical trial
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center TrialStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene RearrangementStatus: Active (not recruiting), Estimated PCD: 2020-09-30
Clinical trial
Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft RecipientsStatus: Withdrawn, Estimated PCD: 2007-11-01
Clinical trial
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-03-28
Clinical trial
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
A Clinical Study Was Conducted to Evaluate the Efficacy and Safety of the RCMOP Regimen Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms TumorStatus: , Estimated PCD: 2016-12-31
Clinical trial
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above (cHL 001)Status: Recruiting, Estimated PCD: 2027-10-03
Clinical trial
Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR StudyStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Clinical trial
Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.Status: Withdrawn, Estimated PCD: 2022-06-01
Clinical trial
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/LeukemiaStatus: Completed, Estimated PCD: 2010-09-01
Clinical trial
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaStatus: Completed, Estimated PCD: 2022-10-20
Clinical trial
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)Status: Withdrawn, Estimated PCD: 2023-07-26
Clinical trial
A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant LeukemiaStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and ChildrenStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell LymphomaStatus: Completed, Estimated PCD: 2002-01-01
Clinical trial
Randomised Placebo Controlled Clinical Trial of Efficacy of MYOcardial Protection in Patients With Postacute inFLAMmatory Cardiac involvEment Due to COVID-19Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-05-22
Clinical trial
Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic TherapyStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCLStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing LymphomasStatus: Active (not recruiting), Estimated PCD: 2028-04-01
Clinical trial
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)Status: Terminated, Estimated PCD: 2015-04-09
Clinical trial
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution StudyStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase I Study of Inotuzumab Ozogamicin With 3 and 4 Drug Augmented Berlin-Frankfurt-Münster (BFM) Re-Induction for Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)Status: Active (not recruiting), Estimated PCD: 2023-07-15
Clinical trial
Effect of Pre-operative Oral Steroids on Blood Loss in Endoscopic Sinus Surgery for Chronic Rhinosinusitis Without PolypsStatus: Withdrawn, Estimated PCD: 2024-03-01
Clinical trial
A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) LeukemiaStatus: Terminated, Estimated PCD: 2010-12-01
Clinical trial
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2019-05-17
Clinical trial
A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular LymphomaStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaStatus: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic AbnormalityStatus: Recruiting, Estimated PCD: 2023-12-25
Clinical trial
A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk ER+/HER2- Early-Stage Breast Cancer (QUEEN-Neo)Status: Not yet recruiting, Estimated PCD: 2025-11-06
Clinical trial
In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues SarcomasStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)Status: Completed, Estimated PCD: 2020-07-02
Clinical trial
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-01-05
Clinical trial
Open Label Safety and Efficacy of Once Weekly Steroid in Patients With LGMD and Becker Muscular DystrophyStatus: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Single-arm, Prospective Clinical Study on the Antitumor Activity and Safety of Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)Status: Active (not recruiting), Estimated PCD: 2015-12-30
Clinical trial
A Multicenter, Randomized, Double Blinded, Placebo-controlled Clinical Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis by the AlcHepNet ConsortiumStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
Steroid Loaded Intranasal Films as a Local Treatment of AnosmiaStatus: Completed, Estimated PCD: 2023-03-18
Clinical trial
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2017-01-01
Clinical trial
A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersStatus: Active (not recruiting), Estimated PCD: 2022-10-11
Clinical trial
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)Status: Terminated, Estimated PCD: 2021-01-20
Clinical trial
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe ColitisStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leukemia (B-ALL)Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)Status: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in AdultsStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Frontline Selinexor(ATG-010) Plus R-CHOP Therapy for High-risk GCB-subtype Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-07-30
Clinical trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Application of Ultrasound Shear Wave Elastography on the Adjunct Corticosteroid Therapy on Tuberculous Lymphadenitis: a Randomized Control TrialStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph NodesStatus: Completed, Estimated PCD: 2010-12-02
Clinical trial
Randomized Phase III Study of Oral Cyclophosphamide vs Doxorubicin in 65 Years or Older Patients With Advanced or Metastatic Soft Tissue Sarcoma: a UNICANCER/GERICO Multicenter ProgramStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid ArthritisStatus: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Study Comparing the Efficacy and Safety of Genotype-guided R-CHOP-X Versus R-CHOP in Patients With Diffuse Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase 2 Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2016-06-27
Clinical trial
A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-08-12
Clinical trial
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-01-07
Clinical trial
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation PneumonitisStatus: Completed, Estimated PCD: 2024-04-12
Clinical trial
Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis in Patients Fifty Years and Older: a Look at Pain and Functional Outcomes at a Single Institution.Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
An Open, Single-arm, Multicenter Study of R-CMOP Protocol for Primary Treatment of Diffuse Large B-cell Lymphoma Based on Cardiac Function ScreeningStatus: Not yet recruiting, Estimated PCD: 2023-08-01
Clinical trial
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant TherapyStatus: Not yet recruiting, Estimated PCD: 2027-07-31
Clinical trial
GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced SarcomaStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic LeukemiaStatus: Completed, Estimated PCD: 2003-06-01
Clinical trial
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder CancerStatus: Recruiting, Estimated PCD: 2026-08-31
Clinical trial
High Dose Oral Steroids in Sudden Sensorineural Hearing LossStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor ColitisStatus: Recruiting, Estimated PCD: 2030-06-30
Clinical trial
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOPStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children: an Open-label Randomized Trial Comparing Anakinra vs sTEroidsStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Multicenter Double-blind Randomized Controlled Trial of Systemic Corticosteroid Therapy in AECOPD Patients Admitted to Hospital With Higher Blood Eosinophil LevelsStatus: Not yet recruiting, Estimated PCD: 2024-01-31
Clinical trial
A Prospective, Randomized Controlled Study to Compare the Efficacy and Safety of Baricitinib Combined With Glucocorticoid and Glucocorticoid Monotherapy in Proliferative IgG4-RD Patients With EosinophiliaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma With Sarcomatoid FeaturesStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENLStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99)Status: Completed, Estimated PCD: 2003-11-01
Clinical trial
A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2030-09-01
Clinical trial
EFFECTIVENESS OF SINGLE DOSE ORAL DEXAMETHASONE VERSUS MULTIDOSE PREDNISOLONE FOR TREATMENT OF ACUTE EXACERBATIONS OF ASTHMA AMONG CHILDREN ATTENDING THE EMERGENCY DEPARTMENT OF CHILDREN HOSPITAL, ISLAMABADStatus: , Estimated PCD: 2023-12-26
Clinical trial
A Prospective Phase Ib/II Trial of Preoperative Radiotherapy Combined With Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-08-24
Clinical trial
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.Status: Completed, Estimated PCD: 2022-11-07
Clinical trial
Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Inoperable PatientsStatus: , Estimated PCD: 2020-06-01
Clinical trial
Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Prospective Randomized Double-blinded Controlled Single Center Clinical Study of the Efficacy and Safety for Tofacitinib Compared With Glucocorticoid in the Remission-reduction Treatment of Active Takayasu's ArteritisStatus: Recruiting, Estimated PCD: 2025-07-20
Clinical trial
Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComasStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
The Registry to Observe Clinical Outcomes of Patients With High-risk Metastatic Hormone-naïve Prostate Cancer in JapanStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Comparison Efficacy of Intraarticular Knee Injection in Knee Osteoarthritis With Leukocyte-rich and Leukocyte-poor Platelet-rich PlasmaStatus: Completed, Estimated PCD: 2022-09-01
Clinical trial
Intra-articular Platelet Rich Plasma vs Corticosteroid in Treatment of Knee OsteoarthritisStatus: Not yet recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's DiseaseStatus: Completed, Estimated PCD: 2011-09-01
Clinical trial
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell LymphomaStatus: Terminated, Estimated PCD: 2014-10-01
Clinical trial
A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast CancerStatus: Completed, Estimated PCD: 2015-07-12
Clinical trial
Corticosteroid Treatment for Community-Acquired Pneumonia to Improve Long-term Cognition: A Pilot Randomized Controlled TrialStatus: Withdrawn, Estimated PCD: 2022-07-30
Clinical trial
Short-course High-dose Prednisone and Dexamethasone in Children With Immune A Multicenter, Randomized Controlled Study of ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin DStatus: Active (not recruiting), Estimated PCD: 2024-02-14
Clinical trial
Three-dimensional Facial Swelling Evaluation of Pre-operative Single-dose of Prednisone in Third Molar Surgery: a Split-mouth Randomized Controlled TrialStatus: Completed, Estimated PCD: 2022-10-25
Clinical trial
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2016-11-12
Clinical trial
Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue SarcomaStatus: Completed, Estimated PCD: 2022-07-17
Clinical trial
Effect of Platelet-Rich Plasma vs Corticosteroid Injection in Distinct Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair: a Multicenter, Three-group, Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2021-06-30
Clinical trial
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy BackbonesStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Prevention of Glucocorticoid Induced Impairment of Bone Metabolism - A Randomized, Placebo-Controlled, Single Centre Clinical TrialStatus: Completed, Estimated PCD: 2022-12-15
Clinical trial
A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast CancerStatus: Completed, Estimated PCD: 2020-03-23
Clinical trial
An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2021-10-15
Clinical trial
Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in ChinaStatus: Completed, Estimated PCD: 2023-09-30
Clinical trial
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain TumorsStatus: Recruiting, Estimated PCD: 2030-08-31
Clinical trial
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic LymphomaStatus: Active (not recruiting), Estimated PCD: 2017-09-30
Clinical trial
The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaStatus: Recruiting, Estimated PCD: 2028-07-31
Clinical trial
Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Retifanlimab (INCMGA00012) in Patients With Selected SarcomasStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)Status: Active (not recruiting), Estimated PCD: 2024-11-15
Clinical trial
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALLStatus: , Estimated PCD: 2025-03-01
Clinical trial
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
To Evaluate the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy and Explore the Possible Mechanism by Using Functional Magnetic Resonance Imaging (fMRI)Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Randomized Phase II Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated SarcomasStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
Double Blinded Prospective Pilot Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) vs. Standard of Care in Adhesive Capsulitis of the ShoulderStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2021-07-16
Clinical trial
A Pilot Study to Access the Feasibility and Safety of Intrathecal Rituximab Added to Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20 Positive Non Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related LymphomasStatus: Recruiting, Estimated PCD: 2025-06-20
Clinical trial
A Multi-Center, Randomized Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in the Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)Status: Completed, Estimated PCD: 2017-09-20
Clinical trial
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19Status: Completed, Estimated PCD: 2022-08-22
Clinical trial
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell LymphomaStatus: Completed, Estimated PCD: 2021-07-20
Clinical trial
Selective CD28 Blockade With Lulizumab Compared to CNI Inhibition With Tacrolimus in Renal Transplant RecipientsStatus: Withdrawn, Estimated PCD: 2022-09-22
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2024-02-02
Clinical trial
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release AloneStatus: Completed, Estimated PCD: 2024-01-23
Clinical trial
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease ActivityStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)Status: Active (not recruiting), Estimated PCD: 2018-10-24
Clinical trial
A Randomized Controlled Trial of Deflazacort vs. Prednisolone in Acute-stage Allergic Bronchopulmonary AspergillosisStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase II, Randomized, Open-label, International, Multicenter Study to Compare Efficacy of Standard Chemotherapy vs. Letrozole Plus Abemaciclib as Neoadjuvant Therapy in HR-positive/HER2-negative High/Intermediate Risk Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-06-21
Clinical trial
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and PrednisoneStatus: Completed, Estimated PCD: 2013-12-10
Clinical trial
A Study to Assess Topoisomerase II Alpha (TOPO2A) as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2021-06-10
Clinical trial
Efficacy and Mechanism of Anti-CD20 Antibodies in Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension Based on Multi Omics StudiesStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort StudyStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)Status: Terminated, Estimated PCD: 2024-02-15
Clinical trial
Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-08-03
Clinical trial
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTSStatus: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2017-07-31
Clinical trial
A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM)Status: Recruiting, Estimated PCD: 2025-01-03
Clinical trial
CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcerStatus: Completed, Estimated PCD: 2018-04-01
Clinical trial
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin LymphomasStatus: , Estimated PCD: 2026-12-01
Clinical trial
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis: A Multicenter, Randomized, Non-inferiority Clinical TrialStatus: Recruiting, Estimated PCD: 2024-09-27
Clinical trial
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Clinical trial
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2030-10-01
Clinical trial
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2030-12-01
Clinical trial
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Status: Recruiting, Estimated PCD: 2025-07-16
Abstract
Edema and serositis as an adverse event in patients with cancer receiving immune checkpoint blockade: Systematic review to evaluate this immune-related adverse event and associated treatment strategies.Org: Mount Sinai Beth Israel, Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).Org: Medical College of Wisconsin, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Wisconsin Madison School of Medicine and Public Health, Division of Hematology & Oncology,
Abstract
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.Org: City of Hope National Medical Center, Genentech, BC Cancer Centre for Lymphoid Cancer, Centre Henri-Becquerel and University of Rouen, University Hospital Münster,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
Feasibility of CAR-T in very old patients with relapsed/refractory diffuse large B-cell lymphoma.Org: H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Doxorubicin to enhance the abscopal effect depending on tumor cell mitochondrial DNA and cGAS/STING.Org: Harbin Medical University Cancer Hospital, West China Hospital, University of Freiburg, Department of Radiation Oncology,
Product
R-CHOPProduct
ADT with or without docetaxel plus abiraterone acetate, prednisone, and prostate radiotherapyProduct
standard polychemotherapyProduct
chemotherapy/immunotherapyProduct
AVA6000Product
Placebo with PrednisoneProduct
abiraterone + prednisoneProduct
docetaxel and prednisoneProduct
Chemotherapy upfrontProduct
IP/IV chemotherapyProduct
Abiraterone, PrednisoneProduct
PrednisoneProduct
ADT plus apalutamideProduct
PDC*lung01 (low dose)Clinical trial
A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in Women With Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-29
Clinical trial
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing LossStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Clinical trial
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients in Treatment of Newly Diagnosed Untreated Non-GCB DLBCL With Extranodal Involvement.Status: , Estimated PCD: 2026-05-01
Clinical trial
A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus NephritisStatus: Completed, Estimated PCD: 2018-09-10
Clinical trial
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases: a Multicentre Randomized, Controlled Double-blind Phase III Study, Comparing Bevacizumab Versus PlaceboStatus: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant SignatureStatus: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
A Multicenter Randomized Controlled Trial to Treat Acute t Cell Mediated Rejection in Kidney and Kidney-pancreas Transplant RecipientsStatus: Not yet recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Study of the Zanubrutinib With G-CHOP Regimens in the Frontline Treatment of Intermediate-high Risk Follicular LymphomaStatus: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
Belatacept With Delayed Tacrolimus Withdrawal Versus Standard-of-Care Tacrolimus in Heart Transplant Recipients (RTB-013)Status: Not yet recruiting, Estimated PCD: 2028-01-31
Clinical trial
A Multicenter, Open-Label, Dose Escalation, Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2016 for Friedreich Ataxia CardiomyopathyStatus: Not yet recruiting, Estimated PCD: 2031-01-31
Clinical trial
Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation: a Randomized, Double Blinded, Multicenter StudyStatus: Recruiting, Estimated PCD: 2025-06-06
Clinical trial
Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2027-06-24
Clinical trial
The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical TrialStatus: Terminated, Estimated PCD: 2024-05-23